We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Symptoms
Hot flashes get the headlines. The other 30+ symptoms — sleep, mood, joints, libido, cognition — are equally hormonal, equally treatable, and equally under-treated. This is the kindr map of all of them.
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
The North American Menopause Society documents more than 30 symptoms tied to the menopause transition. Most women are familiar with two of them. Most clinicians are trained on three. That gap — between what's happening in your body and what's being named in the exam room — is the reason two-thirds of women in the U.S. report being dismissed when they describe their symptoms to a primary care provider.
Every symptom below has a defined hormonal mechanism — what estrogen, progesterone, or testosterone is doing (or not doing) in a specific tissue or pathway — and an evidence-based treatment endorsed by NAMS, ACOG, or the Endocrine Society. We've grouped the 12 most clinically common into the categories your provider would use: vasomotor, cognitive and mood, sleep and energy, metabolic, and genitourinary. Start with the cluster that brought you here.
Last clinically reviewed by Dr. Ana Lisa Carr, MD, MBA on May 10, 2026.
The hypothalamus loses its temperature-regulation calibration as estrogen falls. The same pathway also drives many palpitation episodes women mistake for cardiac events.
Up to 80% of women experience hot flashes during the menopause transition, and on average they continue for 7 to 10 years.
Read the clinical brief →
Roughly 75% of women experience night sweats during the menopause transition; about 30% rate them as severe.
Read the clinical brief →
About 1 in 4 perimenopausal women report new heart palpitations — most are benign and hormonally driven.
Read the clinical brief →
Estrogen receptors are densely concentrated in the prefrontal cortex, hippocampus, and amygdala. When estrogen fluctuates, working memory, verbal recall, and mood regulation are directly impacted — not imagined.
About 60% of women report cognitive complaints during perimenopause — difficulty concentrating, word retrieval problems, and memory lapses.
Read the clinical brief →
Up to 70% of perimenopausal women report new or worsening mood symptoms — irritability, low mood, emotional reactivity, or rage.
Read the clinical brief →
Rates of new-onset anxiety roughly double during the perimenopausal transition compared to premenopause — affecting many women with no prior anxiety history.
Read the clinical brief →
Progesterone is a sleep-supporting hormone. Its decline in perimenopause is one of the most under-recognized drivers of new-onset insomnia in women over 40, which compounds into fatigue, weight gain, and mood instability.
About 56% of perimenopausal and postmenopausal women report sleep disturbance, including difficulty falling asleep, frequent waking (especially at 3 a.m.), and unrefreshing sleep.
Read the clinical brief →
Persistent fatigue is reported by more than 80% of women during the menopause transition.
Read the clinical brief →
The drop in estradiol changes how women store fat, how muscles recover, and how joints retain cartilage. Standard "eat less, move more" advice fails because the underlying metabolic substrate has shifted.
Women gain on average 1.5 lbs per year during the menopause transition, with body fat redistributing to the abdomen even when weight stays stable.
Read the clinical brief →
Roughly 50% of perimenopausal and postmenopausal women report new joint pain or stiffness, sometimes called "menopausal arthralgia."
Read the clinical brief →
GSM (genitourinary syndrome of menopause) affects up to 70% of women and is the most under-treated category. Local estrogen and DHEA are highly effective and carry minimal systemic absorption.
Roughly 40% of women report decreased sexual desire during the menopause transition; for many it is one of the most distressing changes.
Read the clinical brief →
Up to 80% of postmenopausal women experience symptoms of genitourinary syndrome of menopause (GSM), including vaginal dryness, irritation, and pain with intercourse.
Read the clinical brief →
kindr's 8-question symptom checker maps your specific pattern to the most likely hormonal driver and the treatment paths your provider would consider first.
Start the symptom checker →Answers reviewed by Dr. Ana Lisa Carr, MD, MBA, board-certified menopause specialist.
The North American Menopause Society and ACOG recognize over 30 documented symptoms across vasomotor, cognitive, sleep, mood, metabolic, sexual, and musculoskeletal categories. kindr addresses the 12 most clinically common and most treatable.
Aging contributes, but the specific symptom clusters women experience in their 40s and 50s — hot flashes, brain fog, sleep disruption, new-onset anxiety, joint pain, weight redistribution — map directly to estradiol and progesterone decline. Hormone replacement reverses or significantly reduces most of them in clinical studies.
Genitourinary syndrome of menopause (GSM) — vaginal dryness, urinary frequency, painful intercourse — is the most under-treated. It affects up to 70% of postmenopausal women and is highly responsive to local estrogen, yet fewer than 7% receive treatment for it.
Per current NAMS and ACOG guidance, hormone therapy is prescribed based on symptoms and clinical history in healthy women under 60 within 10 years of menopause — not on lab numbers. FSH and estradiol levels fluctuate too widely in perimenopause to be diagnostic.
Yes. The perimenopause transition typically begins 4 to 10 years before the final menstrual period. Onset in the late 30s is well-documented, especially symptoms like sleep disruption, mood changes, and irregular cycles. Early-onset perimenopause is not premature ovarian insufficiency.
Hot flashes and night sweats respond to systemic estrogen within 1 to 2 weeks. Sleep and mood typically improve within 2 to 4 weeks. Brain fog and energy can take 6 to 12 weeks. GSM symptoms respond to local estrogen within 2 to 6 weeks.
Yes — and this is the single most common reason women are dismissed. Estradiol can fluctuate from postmenopausal levels to premenopausal levels within the same month during perimenopause. A "normal" lab snapshot does not rule out hormonal symptoms.
Yes, for women who cannot or prefer not to use HRT. Fezolinetant (Veozah), paroxetine (Brisdelle), gabapentin, and certain SSRIs/SNRIs are evidence-based options for vasomotor symptoms. Cognitive behavioral therapy for insomnia (CBT-I) has strong data for sleep.
A 10-minute intake. A board-certified provider in your state. A personalized plan within 24 hours.
Start your visit →